Corvus Pharmaceuticals Inc (NASDAQ:CRVS) Insider Richard A. Md Miller Acquires 15,212 Shares

Share on StockTwits

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) insider Richard A. Md Miller purchased 15,212 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The shares were purchased at an average cost of $3.49 per share, with a total value of $53,089.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CRVS stock traded down $0.11 during trading on Friday, hitting $3.53. 7,221 shares of the stock traded hands, compared to its average volume of 69,996. Corvus Pharmaceuticals Inc has a one year low of $3.22 and a one year high of $13.91. The company has a debt-to-equity ratio of 0.03, a current ratio of 12.39 and a quick ratio of 12.39.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.40). On average, research analysts predict that Corvus Pharmaceuticals Inc will post -1.61 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BVF Inc. IL raised its stake in shares of Corvus Pharmaceuticals by 11.6% in the first quarter. BVF Inc. IL now owns 2,109,342 shares of the company’s stock worth $8,480,000 after acquiring an additional 218,835 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Corvus Pharmaceuticals by 18.0% in the first quarter. Renaissance Technologies LLC now owns 781,700 shares of the company’s stock worth $3,142,000 after acquiring an additional 119,400 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Corvus Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 677,974 shares of the company’s stock worth $5,817,000 after acquiring an additional 13,578 shares during the last quarter. Vanguard Group Inc raised its stake in shares of Corvus Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc now owns 677,974 shares of the company’s stock worth $5,817,000 after acquiring an additional 13,578 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Corvus Pharmaceuticals by 25.3% in the first quarter. Dimensional Fund Advisors LP now owns 421,280 shares of the company’s stock worth $1,693,000 after acquiring an additional 84,953 shares during the last quarter. 84.46% of the stock is owned by institutional investors.

Several brokerages recently issued reports on CRVS. Zacks Investment Research downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 20th. Wedbush cut their price target on shares of Corvus Pharmaceuticals from $19.00 to $11.00 and set an “outperform” rating for the company in a report on Wednesday, March 13th. Finally, Roth Capital began coverage on shares of Corvus Pharmaceuticals in a report on Wednesday, May 29th. They set a “buy” rating and a $6.00 price target for the company. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $9.19.

WARNING: This news story was published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4371419/corvus-pharmaceuticals-inc-nasdaqcrvs-insider-richard-a-md-miller-acquires-15212-shares.html.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Featured Story: The Discount Rate – What You Need to Know

Insider Buying and Selling by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Gol Linhas Aereas Inteligentes SA  to Issue … Dividend of $0.00 on  June 28th
Gol Linhas Aereas Inteligentes SA to Issue … Dividend of $0.00 on June 28th
Enanta Pharmaceuticals Inc  Receives Average Rating of “Buy” from Brokerages
Enanta Pharmaceuticals Inc Receives Average Rating of “Buy” from Brokerages
China Unicom  Limited  Receives Average Recommendation of “Buy” from Brokerages
China Unicom Limited Receives Average Recommendation of “Buy” from Brokerages
$0.93 EPS Expected for CGI Inc  This Quarter
$0.93 EPS Expected for CGI Inc This Quarter
Flexion Therapeutics Inc  Expected to Post Earnings of -$1.06 Per Share
Flexion Therapeutics Inc Expected to Post Earnings of -$1.06 Per Share
General Dynamics Co.  Receives Consensus Rating of “Hold” from Analysts
General Dynamics Co. Receives Consensus Rating of “Hold” from Analysts


© 2006-2019 Ticker Report